Brief: Brickell Biotech Reports Results From U.S. Phase 3 Open-Label, Long-Term Safety Study On Chronic Use Of Sofpironium Bromide Gel As A Potential Treatment For Primary Axillary Hyperhidrosis
23/04/2021 16:55
April 23 (Reuters) - Brickell Biotech Inc BBI.O :
* BRICKELL BIOTECH REPORTS RESULTS FROM U.S. PHASE 3
OPEN-LABEL,
LONG-TERM SAFETY STUDY ON CHRONIC USE OF SOFPIRONIUM BROMIDE GEL
AS A POTENTIAL TREATMENT FOR PRIMARY AXILLARY HYPERHIDROSIS
* BRICKELL BIOTECH INC - DAILY TREATMENT WITH SOFPIRONIUM
BROMIDE
GEL WAS GENERALLY WELL-TOLERATED OVER 48 WEEKS OF TREATMENT
Source text for Eikon: urn:newsml:reuters.com:*:nGNX6W7TDt
Further company coverage: BBI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fresh Tracks Therapeutics
See all newsBrief: Fresh Tracks Therapeutics Announces Second Adjournment Of Special Meeting Of Stockholders
Brief: Fresh Tracks Therapeutics Intends To Seek Judicial Dissolution If Liquidation And Approved By Stockholders
Brief: Fresh Tracks Therapeutics Q3 EPS USD 0.32
Brief: Fresh Tracks Therapeutics Inc On October 10 Received A Notice From Listing Qualifications Department Of Nasdaq
U.S. STOCKS ON THE MOVE-Gold miners, Goosehead Insurance, FedEx